How I manage polycythemia
Polycythemia is suspected when hemoglobin and/or hematocrit levels exceed established norms based on gender and age. This biological anomaly can arise from a myeloproliferative neoplasm known as polycythemia vera, or be secondary to excess erythropoietin (EPO) or decreased in plasma volume. Faced with polycythemia, the search for JAK2 mutations and measurement of serum EPO levels can guide toward the etiology. In polycythemia vera, thromboembolic events are the most lethal complications and unfortunately often the initial manifestation of the disease. The condition can also progress to myelofibrosis or acute leukemia. Management aims at reducing the hematocrit below 45 %, in order to limit, but not completely prevent, thrombo-embolic complications. This article elaborates on the clinical considerations around this biological anomaly, relevant complementary examinations, and briefly the therapeutic management.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Revue medicale de Liege - 79(2024), 2 vom: 31. Feb., Seite 110-115 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Comment j’explore … une polyglobulie |
|---|
| Beteiligte Personen: |
Lombardo, Gérôme [VerfasserIn] |
|---|
| Themen: |
EC 2.7.10.2 |
|---|
| Anmerkungen: |
Date Completed 16.02.2024 Date Revised 22.02.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM368465284 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368465284 | ||
| 003 | DE-627 | ||
| 005 | 20240222232629.0 | ||
| 007 | tu | ||
| 008 | 240215s2024 xx ||||| 00| ||fre c | ||
| 028 | 5 | 2 | |a pubmed24n1302.xml |
| 035 | |a (DE-627)NLM368465284 | ||
| 035 | |a (NLM)38356428 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Lombardo, Gérôme |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How I manage polycythemia |
| 246 | 3 | 3 | |a Comment j’explore … une polyglobulie |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2024 | ||
| 500 | |a Date Revised 22.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Polycythemia is suspected when hemoglobin and/or hematocrit levels exceed established norms based on gender and age. This biological anomaly can arise from a myeloproliferative neoplasm known as polycythemia vera, or be secondary to excess erythropoietin (EPO) or decreased in plasma volume. Faced with polycythemia, the search for JAK2 mutations and measurement of serum EPO levels can guide toward the etiology. In polycythemia vera, thromboembolic events are the most lethal complications and unfortunately often the initial manifestation of the disease. The condition can also progress to myelofibrosis or acute leukemia. Management aims at reducing the hematocrit below 45 %, in order to limit, but not completely prevent, thrombo-embolic complications. This article elaborates on the clinical considerations around this biological anomaly, relevant complementary examinations, and briefly the therapeutic management | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Erythrocytosis | |
| 650 | 4 | |a Erythropoietin | |
| 650 | 4 | |a JAK2 mutation | |
| 650 | 4 | |a Polycythemia vera | |
| 650 | 4 | |a Vaquez disease | |
| 650 | 7 | |a Janus Kinase 2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 700 | 1 | |a Hafraoui, Kaoutar |e verfasserin |4 aut | |
| 700 | 1 | |a Beguin, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Vertenoeil, Gaëlle |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale de Liege |d 1947 |g 79(2024), 2 vom: 31. Feb., Seite 110-115 |w (DE-627)NLM000044490 |x 0370-629X |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2024 |g number:2 |g day:31 |g month:02 |g pages:110-115 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2024 |e 2 |b 31 |c 02 |h 110-115 | ||